论文部分内容阅读
目的：将抗人原发性肝癌（ＰＬＣ）单抗ＴＩＧＴＣⅢ，用胃蛋白酶法消化成Ｆ（ａｂ′）２片段，标记１３１Ｉ后进行裸鼠人肝癌移植瘤的体内定位研究。方法：采用胃蛋白酶消化法，进行裸鼠体内核素显像。结果：消化产率为３１７％±２４％，经细胞结合实验证明Ｆ（ａｂ′）２具有良好的免疫活性，抗体片段进入裸鼠体内后，与完整抗体比，进入肿瘤的速度快，生物学分布特异性高，定位指数上升，血清本底下降迅速，生物半衰期明显缩短。结论：Ｆ（ａｂ′）２与全抗体比较可使成像时间提前，定位清晰
OBJECTIVE: To study the in vivo targeting of human hepatocellular carcinoma xenografts in nude mice by digesting TIGTCⅢ anti-human primary hepatoma (PLC) monoclonal antibody with F (ab ’) 2 fragment by pepsin and labeling with 131I. Methods: Gastric nuclide imaging was performed in nude mice by pepsin digestion. Results: The digestion rate was 317% ± 24%. F (ab ’) 2 was proved to be immunologically active by cell binding assay. After the antibody fragments entered the nude mice, the rate of entering the tumor was higher than that of the intact antibody Fast, high specificity of biological distribution, positioning index increased rapidly decline in serum background, biological half-life was significantly shortened. Conclusion: Compared with the whole antibody, F (ab ’) 2 can make the imaging time ahead and clear the location